
Year in Review
Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke
| Stockhead TV
Link copied to clipboard
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies.
In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.
Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.
To hear about the company’s upcoming 2023, click above.
Link copied to clipboard
Get the latest Stockhead news delivered free to your inbox.
"*" indicates required fields
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
Year in Review
| Stockhead TV
Prepped and Primed
| Stockhead TV
Health & Biotech
| Nadine McGrath
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。